Both the Kidney Disease Improving Global Outcomes guidelines and American Diabetes Association Standards of Care recommend GLP1-RA as the preferred glucose lowering class for people with T2D and moderate to advanced CKD or ESRD because of their demonstrated cardiovascular benefits in people with T2D at high risk of cardiovascular disease, which includes CKD 13,14
The FDAs stated reason: there is no clinical need for outsourcing facilities to compound these drugs from bulk API now that supply is stable
In Australia, healthcare providers are increasingly considering the adoption of needleless options, recognising their potential to enhance patient care
Can lipotropic injections replace diet and exercise for weight loss? No lipotropic injections facilitate hepatic fat export by supporting phosphatidylcholine synthesis, but they cannot override caloric surplus
The Primary Care Companion for CNS Disorders, 23 (4), 20m02747
Certificate of Analysis Every batch of Epithalon sold by Pepspan undergoes rigorous third-party testing